Knobbe Martens
Harnik Shukla is a Partner at Knobbe Martens, recognized for excellence in Patent Prosecution, earning accolades from The Legal 500 as a "Leading Lawyer" and noted in the Best Lawyers: Ones to Watch guide for Intellectual Property Law. Harnik has also been featured in IAM Strategy 300 for expertise in IP strategy and named a "Rising Star" in the LMG Life Sciences Guide. Harnik's prior experience includes roles as an Associate at the United States District Court and as a Summer Associate at multiple law firms, alongside a strong educational background with a JD from UC Irvine and advanced degrees in Electrical and Electronics Engineering from the University of Toronto.
This person is not in any teams
Knobbe Martens
2 followers
Our firm boasts IP law’s largest and most experienced biotechnology group, with more than 60 attorneys and scientists representing clients in all stages of their business and technology development. Our clients are innovators in a variety of disciplines including PCR, molecular tools and probes, immunology (antibodies and other binding proteins), cell varieties and uses (including stem cells) and biological polymers, to name but a few. Our expertise across the entire biotech landscape gives us great insight into specific technologies, systems and markets. More importantly, our holistic understanding of the interrelated technologies and systems typically involved in a single invention allows us to provide coordinated guidance and counsel from inception though introduction. Working in collaboration with more than 300 IP firms worldwide, we effect patent, trademark, copyright, and other filings, and direct oppositions, cancellations, and litigation matters in over 120 countries. We have considerable experience in negotiating and drafting traditional licensing agreements as well as agreements for strategic alliances, partnerships and joint ventures. We also maintain a talented litigation department adept in all aspects of biotechnology IP law, including the Biosimilars legislation. Our extensive Hatch-Waxman litigation experience combined with our understanding of the biotechnology industry uniquely positions Knobbe Martens to help clients develop and implement litigation strategies designed to maximize their place in the Biosimilars market place. In addition, we have considerable experience litigating before the U.S. Court of Appeals for the Federal Circuit and the International Trade Commission. Our attorneys have experience in all areas of Biotechnology, including: Aesthetic & Cosmetic Biotechnology Antibodies & Immunology Biofuels Biological Manufacturing Of Chemicals Biologics Diagnostic Tools Genomics Industrial Enzymes Peptides Personalized Medicine Research Tools & Reagents Stem Cells & Regenerative Medicine Synthetic Biology & Nanotechnology Therapeutics Tissue Engineering Transgenic Animals Vaccines